Importantly, our preclinical and human-relevance studies demonstrate the therapeutic potential of targeting ASH1L in metastatic bone tumors, providing insights into targeted therapies in patients with lethal malignancies. The gene discussed is ASH1L; the disease is bone neoplasm.